ClinicalTrials.gg

Parkinson Disease clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 4,580 studies for Parkinson Disease across more than 10 countries. 1,086 are recruiting or about to start. 4,106 of them are mainly about Parkinson Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 5,078 studies for Parkinson Disease. How that becomes 4,576 here

This page counts the studies the registry files under Parkinson Disease, and those it files under no condition that list Parkinson Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 5,078Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −48List Parkinson Disease as a condition, but the registry did not file them under itMost often written as “Parkinson Disease Dementia” (10), “Parkinson's Disease Dementia” (6), and “Advanced Parkinson's Disease” (5). The registry filed them under other conditions only, most often Lewy Body Disease (21) and Alzheimer Disease (12).
  3. −454Match it another way130 name it in the title, 8 in a keyword, and 316 by a synonym or other text the search reads.
  4. 4,576The count on this page78 of them list Parkinson Disease in their own words; the registry filed them under no condition.

Status

Completed
2,421
Recruiting
750
Status unknown
513
Terminated
254
Not yet recruiting
251
Active, not recruiting
176

Phase

Phase 2
621
Phase 1
441
Phase 3
304
Phase 4
179
Early Phase 1
59

Where

United States
1,649
France
428
Italy
348
China
279
Germany
264
Canada
253

Who develops what

Add Parkinson Disease to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 58 programs from 47 companies, 53 with this as their studies’ main aim; 7 with a live phase 3 study; 13 primary completions in the next 12 months. Compare Bayer, Energenesis Biomedical and Hoffmann-La Roche here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
LevodopaEarlier only
Evidence
  • NCT04380142 · AbbVie · Phase 3 · comparator · “Levodopa/Carbidopa (LD/CD)” · registered May 2020
  • NCT03541356 · impel pharmaceuticals · Phase 2 · comparator · “L-dopa 35 mg” · registered Apr 2018
  • NCT03103399 · Bial - Portela C S.A. · Phase 2 · background · “Levodopa/DDCI” · registered Mar 2017
  • NCT03000569 · Biogen · Phase 2 · background · “Levodopa” · registered Nov 2016
  • NCT02641054 · CleveXel Pharma · Phase 2 · background · “Levodopa” · registered Dec 2015
Acorda Therapeutics25% of its industry studiesUS: off-patent, 20 generics marketedEU: Merz Pharma (EMA 2019)00 studies
CarbidopaEarlier only
Evidence
  • NCT04380142 · AbbVie · Phase 3 · comparator · “Levodopa/Carbidopa (LD/CD)” · registered May 2020
  • NCT01568047 · Bial - Portela C S.A. · Phase 2 · background · “Levodopa/Carbidopa” · registered Mar 2012
  • NCT01568073 · Bial - Portela C S.A. · Phase 3 · background · “Carbidopa” · registered Mar 2012
  • NCT01568034 · Bial - Portela C S.A. · Phase 2 · background · “Levodopa/Carbidopa” · registered Mar 2012
  • NCT01227655 · Bial - Portela C S.A. · Phase 3 · background · “Carbidopa” · registered Oct 2010
Novartis32% of its industry studiesUS: off-patent, 24 generics marketed00 studies
entacaponeEarlier only
Evidence
  • NCT03103399 · Bial - Portela C S.A. · Phase 2 · comparator · “Comtan®” · registered Mar 2017
  • NCT02834507 · Bial - Portela C S.A. · Phase 2 · comparator · “Comtan®” · registered Jul 2016
  • NCT01883505 · Tanabe Pharma Corporation · Phase 2 · background · “Entacapone” · registered Jun 2013
  • NCT01568073 · Bial - Portela C S.A. · Phase 3 · comparator · “Entacapone” · registered Mar 2012
  • NCT01130493 · Amneal Pharmaceuticals, Inc. · Phase 3 · background · “CLE” · registered May 2010
Novartis80% of its industry studiesUS: off-patent, 8 generics marketedEU: off-patent, 1 generic authorized00 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
BHV-8000☆ Track1 live phase-3 study: NCT06976268Biohaven Therapeutics Ltd.
VG081821AC☆ Track1 live phase-3 study: NCT07725562Zhejiang Vimgreen Pharmaceuticals, Ltd.
TJ0113☆ Track1 live phase-3 study: NCT07741045Hangzhou PhecdaMed Co., Ltd.
bemdaneprocel☆ Track1 live phase-3 study: NCT06944522Bayer
prasinezumab☆ Track1 live phase-3 study: NCT07174310Hoffmann-La Roche

The 5 in phase 3 with the nearest primary completion, of 58 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (13)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 28 Nov 2026 est.TB006 · TrueBinding, Inc. · Phase 2 main aimNCT06773962 A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease — primary endpoint: Change from Baseline in Parkinson's Disease Rating Scale Score · 62 enrolled
  • Dec 2026 est.Human Dopaminergic Progenitor Cells · iRegene Therapeutics Co., Ltd. · Phase 2 main aimNCT07028632 The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease — primary endpoint: Motor Function · 30 enrolled
  • 31 Dec 2026 est.HBI-002 · Hillhurst Biopharmaceuticals, Inc. · Phase 2 main aimNCT07005180 Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease — primary endpoint: Frequency and severity of treatment-emergent AEs related to HBI-002 compared to placebo. · 36 enrolled

10 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Parkinson Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Local anesthetics 3 open · Dopamine agonists 2 open · Cholinesterase inhibitors 2 open · Serotonin receptor agonists 2 open · Antipsychotics 2 open

Coming up

389studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger. 64 (9%) take children under 18. 2 (<1%) are for women only and 3 (<1%) for men only; 189 (25%) take healthy volunteers.

Recruiting studies that take each age, of 750
AgeWomenMen
1061 (8%)61 (8%)
18364 (49%)363 (48%)
30459 (61%)457 (61%)
40586 (78%)584 (78%)
50730 (97%)728 (97%)
65738 (98%)740 (99%)
75690 (92%)689 (92%)
85471 (63%)470 (63%)

Across all 4,580 studies, recruiting or not: 18% stop at 75 or younger and 4% at 65; 9% take children; <1% are for women only and 1% for men only; 22% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Parkinson Disease studies take

Of 204 phase 1 interventional studies under Parkinson Disease, half reached primary completion within 18 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 118 mo5–40 · 204 studies9 mo3–24 · 127 studies37 mo20–68 · 77 studies
Phase 1/225 mo12–53 · 55 studies——
Phase 228 mo16–44 · 202 studies19 mo13–33 · 97 studies35 mo24–59 · 105 studies
Phase 2/322 mo18–50 · 22 studies——
Phase 335 mo22–56 · 67 studies31 mo20–54 · 39 studies—
Phase 428 mo19–65 · 57 studies—41 mo21–75 · 42 studies
Interventional, no phase25 mo12–44 · 1,371 studies27 mo17–43 · 76 studies24 mo11–44 · 1,295 studies
Observational47 mo22–114 · 440 studies37 mo19–64 · 60 studies48 mo22–133 · 380 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting14

Show 9 more

Newly registered37

Show 32 more

Studies

Recruiting first, then most recently updated. Showing 50 of 4,580. Browse all 4,580 → or search them.